deltatrials
Unknown PHASE2 NCT00003123

Amifostine in Treating Patients With Advanced Myelodysplastic Syndrome

A Phase II Trial of Ethyol (Amifostine) in Adult Patients With Advanced Myelodysplastic Syndromes

Sponsor: Providence Hospital

Conditions Myelodysplastic Syndromes
Interventions amifostine trihydrate
Updated 5 times since 2017 Last updated: Nov 5, 2013 Started: Aug 31, 1997

This PHASE2 trial investigates Myelodysplastic Syndromes and is currently ongoing. Providence Hospital leads this study, which shows 5 recorded versions since 1997 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotUnknown Status~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotUnknown Status~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – present · 19 months · monthly snapshotUnknown

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE2

    Status: Unknown Status → Unknown

  3. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Unknown Status PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Unknown Status PHASE2

    First recorded

Aug 1997

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Providence Hospital
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations